Hydrogen project investments are accelerating but uncertainty remains, IEA says
What are the key issues in Mozambique elections?
Danish police investigate two blasts near Israel's embassy in Copenhagen
2 predawn explosions rock the area around the Israeli Embassy in Copenhagen but no one is injured
Lebanese emergency services are overwhelmed and need better gear to save lives in wartime
Israel warns people to evacuate another 24 villages in southern Lebanon
Worries over Middle East escalation weigh
Kenya's inflation falls to 3.6% in Sept
Futures in Japan face hangover from BOJ's bond-buying binge
Tatis hits 2-run homer, King strikes out 12 as the Padres beat the Braves 4-0 in playoff opener
Liberty top Aces 88-84 to take a 2-0 lead in the WNBA semifinals and put the champs on the brink
Atlanta rapper Rich Homie Quan died from an accidental drug overdose, medical examiner says
(Reuters) -Teva Pharmaceuticals said on Monday it had launched a generic version of Novo Nordisk's Victoza to treat patients with type 2 diabetes, making it the first generic GLP-1 drug in the United States where the drug class has seen overwhelming demand.
GLP-1 drugs, originally approved to treat diabetes, are also prescribed for obesity.
The growing popularity of GLP-1 drugs such as Eli Lilly's Mounjaro and Danish drugmaker Novo's Wegovy has resulted in intermittent shortages over the past year and drugmakers are racing to increase supply.
But demand for Victoza, a first-generation GLP-1, has been on a decline with the loss of patent protection last year and as patients move towards once-weekly and tablet-based treatments, according to Novo.
Victoza, chemically known as liraglutide, is a once-daily injection approved for use in adults and children aged 10 or older with type 2 diabetes.
The drug brought in annual sales of $1.66 billion as of April 2024, according to Teva.
Teva's generic launch comes days after the U.S. Food and Drug Administration tentatively approved London-based Hikma Pharmaceuticals' generic version of Victoza, according to the agency's website.
Hikma did not immediately respond to a Reuters request for comment.
($1 = 6.9510 Danish crowns)
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber, Devika Syamnath and Shinjini Ganguli)
